Article Speculates AMAG Pharmaceuticals (AMAG) Could Be A Takeover Target
Tweet
Share
E-mailGet Alerts AMAG Hot Sheet
Join SI Premium – FREE
TheStreet.com's biotech guru, Adam Feuerstein, speculates that AMAG Pharmaceuticals (Nasdaq: AMAG) could be the target of a takeover, following last week's approval of Feraheme for intravenous use as an iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.
Feuerstein contends, ... the changing landscape for treatment of dialysis and pre-dialysis patients, especially the specter of Medicare dialysis bundling looming in the near future, also means that incumbent players in this market need to take big steps to ensure their future success.
According to Feuerstein, some potential suitors for AMAG includes Genzyme (Nasdaq: GENZ), Amgen (Nasdaq: AMGN), Johnson & Johnson (NYSE: JNJ) and Davita (NYSE: DVA).
Feuerstein contends, ... the changing landscape for treatment of dialysis and pre-dialysis patients, especially the specter of Medicare dialysis bundling looming in the near future, also means that incumbent players in this market need to take big steps to ensure their future success.
According to Feuerstein, some potential suitors for AMAG includes Genzyme (Nasdaq: GENZ), Amgen (Nasdaq: AMGN), Johnson & Johnson (NYSE: JNJ) and Davita (NYSE: DVA).
You May Also Be Interested In
- Sixth Street renews bid for Brighthouse Financial amid rival deal delays
- US Proposed Extending China Trade Truce By Six Months - NYT
- Royal Caribbean Nears Deal For Sandals - FT
Create E-mail Alert Related Categories
Insiders' Blog, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
